Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT201406018323N10
IRCT201406018323N10
Completed
Phase 4

The evaluation of the efficacy and safety of oral fingolimod in relapsing remitting multiple sclerosis

Vice-chancellor for research, Kermanshah University of Medical Sciences0 sites60 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsmultiple sclerosis.Disseminated Multiple Sclerosis

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
multiple sclerosis.
Sponsor
Vice-chancellor for research, Kermanshah University of Medical Sciences
Enrollment
60
Status
Completed
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice-chancellor for research, Kermanshah University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •1\.Patients with Relapsing\- Remitting Multiple Sclerosis (RRMS) based on McDonald's Criteria (2010\)
  • •2\.age between 18 to 45 years
  • •3\. EDSS between 0 to 5\.5
  • •4\. at least one relapse in previous year while receiving first line disease modifying therapy
  • •5\.at least 2 relapses in previous 2 years while receiving first line disease modifying therapy
  • •6\. no relapses in 30 days previous to fingolimod initiation
  • •7\. negative pregnancy tests in child bearing women
  • •8\. positive history of varicella zoster virus vaccination or positive anti varicella zoster antibody in serum
  • •Exclusion criteria:
  • •1\. primary or secondary progressive MS

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 3
Study to compare the effectiveness and safety of two drugs in atopic dermatitis in childre
CTRI/2024/02/063274IMS and SUM Hospital
Not yet recruiting
Not Applicable
To observe the efficacy of oral fluconazole versus 5% amrolfine nail lacquer in the patients of Onychomycosis.Health Condition 1: L609- Nail disorder, unspecified
CTRI/2020/12/029904Dr Ruchir M Bhatt
Completed
Not Applicable
Effectiveness and safety of oral and intralesional tranexamic acid in treatment of melasmaHealth Condition 1: L811- ChloasmaHealth Condition 2: O- Medical and Surgical
CTRI/2021/08/035350Department of Dermatology42
Not yet recruiting
Not Applicable
Study to evaluate the effectiveness and safety of drug- oral tofacitinib in patients with Parthenium dermatitis
CTRI/2023/10/058514AIIMS, New Delhi
Completed
Phase 3
se of Zonisamide oral medicine in children with epilepsy West Syndrome
CTRI/2013/07/003843PGIMER30